KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) EBT (2016 - 2025)

Jazz Pharmaceuticals has reported EBT over the past 16 years, most recently at $208.5 million for Q4 2025.

  • Quarterly EBT rose 56.49% to $208.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$384.8 million through Dec 2025, down 181.82% year-over-year, with the annual reading at -$627.9 million for FY2025, 233.49% down from the prior year.
  • EBT was $208.5 million for Q4 2025 at Jazz Pharmaceuticals, up from $9.0 million in the prior quarter.
  • Over five years, EBT peaked at $208.5 million in Q4 2025 and troughed at -$735.6 million in Q2 2025.
  • The 5-year median for EBT is $21.0 million (2022), against an average of -$12.4 million.
  • Biggest five-year swings in EBT: plummeted 658.41% in 2022 and later surged 771.16% in 2023.
  • Tracing JAZZ's EBT over 5 years: stood at -$44.8 million in 2021, then plummeted by 658.41% to -$340.0 million in 2022, then skyrocketed by 118.1% to $61.5 million in 2023, then surged by 116.52% to $133.2 million in 2024, then soared by 56.49% to $208.5 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at $208.5 million, $9.0 million, and -$735.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.